No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
AUTL Autolus Therapeutics
- 2.290
- +0.050+2.23%
Close Dec 20 16:00 ET
- 2.330
- +0.040+1.75%
Post 20:01 ET
609.42MMarket Cap-1.88P/E (TTM)
2.350High2.200Low2.61MVolume2.230Open2.240Pre Close5.96MTurnover1.94%Turnover RatioLossP/E (Static)266.12MShares7.45052wk High1.28P/B307.94MFloat Cap2.20052wk Low--Dividend TTM134.47MShs Float53.240Historical High--Div YieldTTM6.70%Amplitude1.600Historical Low2.280Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Reported Earlier, Autolus Therapeutics Revealed New Data Supporting Obe-cel's Clinical And Economic Benefits At ASH 2024
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics: Undervalued Potential in ALL Treatment With Obe-cel
Autolus Therapeutics Plc (AUTL): A Bull Case Theory
Positive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T Therapy
Heat List
US
Overall
Symbol
Price
% Chg
No Data